Blaney Davidson, E.N., van Caam, A.P., Vitters, E.L., Bennink, M.B., Thijssen, E., van den Berg, W.B., Koenders, M.I., van Lent, P.L., van de Loo, F.A., van der Kraan, P.M., TGF-beta is a potent inducer of Nerve Growth Factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain?. Osteoarthritis Cartilage 23 (2015), 478–486.
Goldring, M.B., Otero, M., Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23 (2011), 471–478.
Ding, L., Heying, E., Nicholson, N., Stroud, N.J., Homandberg, G.A., Buckwalter, J.A., Guo, D., Martin, J.A., Mechanical impact induces cartilage degradation via mitogen activated protein kinases. Osteoarthritis Cartilage 18 (2010), 1509–1517.
Gosset, M., Berenbaum, F., Levy, A., Pigenet, A., Thirion, S., Cavadias, S., Jacques, C., Mechanical stress and prostaglandin E2 synthesis in cartilage. Biorheology 45 (2008), 301–320.
Kaiser, M.J., Hauzeur, J.P., Blacher, S., Foidart, J.M., Deprez, M., Rossknecht, A., Malaise, M.G., Contrast-enhanced coded phase-inversion harmonic sonography of knee synovitis correlates with histological vessel density: 2 automated digital quantifications. J. Rheumatol. 36 (2009), 1391–1400.
Scanzello, C.R., Goldring, S.R., The role of synovitis in osteoarthritis pathogenesis. Bone 51 (2012), 249–257.
Gomez, R., Villalvilla, A., Largo, R., Gualillo, O., Herrero-Beaumont, G., TLR4 signalling in osteoarthritis–finding targets for candidate DMOADs. Nature Rev. Rheumatol. 11 (2015), 159–170.
Taniguchi, N., Kawakami, Y., Maruyama, I., Lotz, M., HMGB proteins and arthritis. Hum. Cell 31 (2018), 1–9.
Chan, D.D., Xiao, W.F., Li, J., de la Motte, C.A., Sandy, J.D., Plaas, A., Deficiency of hyaluronan synthase 1 (Has1)results in chronic joint inflammation and widespread intra-articular fibrosis in a murine model of knee joint cartilage damage. Osteoarthritis Cartilage 23 (2015), 1879–1889.
Deroyer, C., Charlier, E., Neuville, S., Malaise, O., Gillet, P., Kurth, W., Chariot, A., Malaise, M., Seny, D., CEMIP (KIAA1199)induces a fibrosis-like process in osteoarthritic chondrocytes. Cell Death Dis., 10, 2019, 103.
Chan, D.D., Li, J., Luo, W., Predescu, D.N., Cole, B.J., Plaas, A., Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury. J. Orthopaedic Res. 36 (2018), 365–376.
Jeon, O.H., Kim, C., Laberge, R.M., Demaria, M., Rathod, S., Vasserot, A.P., Chung, J.W., Kim, D.H., Poon, Y., David, N., Baker, D.J., van Deursen, J.M., Campisi, J., Elisseeff, J.H., Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23 (2017), 775–781.
Vinatier, C., Dominguez, E., Guicheux, J., Carames, B., Role of the inflammation-autophagy-senescence integrative network in osteoarthritis. Front. Physiol., 9, 2018, 706.
Courties, A., Gualillo, O., Berenbaum, F., Sellam, J., Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage 23 (2015), 1955–1965.
Wang, X., Hunter, D., Xu, J., Ding, C., Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage 23 (2015), 22–30.
Singer, J.W., Fleischman, A., Al-Fayoumi, S., Mascarenhas, J.O., Yu, Q., Agarwal, A., Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1)as a therapeutic strategy. Oncotarget 9 (2018), 33416–33439.
Leaf, I.A., Nakagawa, S., Johnson, B.G., Cha, J.J., Mittelsteadt, K., Guckian, K.M., Gomez, I.G., Altemeier, W.A., Duffield, J.S., Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. J. Clin. Investig. 127 (2017), 321–334.
Kelly, P.N., Romero, D.L., Yang, Y., Shaffer, A.L. 3rd, Chaudhary, D., Robinson, S., Miao, W., Rui, L., Westlin, W.F., Kapeller, R., Staudt, L.M., Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J. Exp. Med. 212 (2015), 2189–2201.
Baker, K., Grainger, A., Niu, J., Clancy, M., Guermazi, A., Crema, M., Hughes, L., Buckwalter, J., Wooley, A., Nevitt, M., Felson, D.T., Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann. Rheum. Dis. 69 (2010), 1779–1783.
Kloppenburg, M., Ramonda, R., Bobacz, K., Kwok, W.Y., Elewaut, D., Huizinga, T.W.J., Kroon, F.P.B., Punzi, L., Smolen, J.S., Vander Cruyssen, B., Wolterbeek, R., Verbruggen, G., Wittoek, R., Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77 (2018), 1757–1764.
Bay-Jensen, A.C., Thudium, C.S., Mobasheri, A., Development and use of biochemical markers in osteoarthritis: current update. Curr. Opin. Rheumatol. 30 (2018), 121–128.
Mobasheri, A., van Spil, W.E., Budd, E., Uzieliene, I., Bernotiene, E., Bay-Jensen, A.C., Larkin, J., Levesque, M.C., Gualillo, O., Henrotin, Y., Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes. Curr. Opin. Rheumatol. 31 (2019), 80–89.
